President Donald Trump may occasionally erupt with passionate criticism for biopharma companies and the execs who run them, but once again he’s going with an industry insider for a top government post. The nation’s 45th president just tweeted that he has nominated Alex Azar as the next secretary of Health and Human Services.
Happy to announce, I am nominating Alex Azar to be the next HHS Secretary. He will be a star for better healthcare and lower drug prices!
— Donald J. Trump (@realDonaldTrump) November 13, 2017
“He will be a star for better healthcare and lower drug prices!,” Trump exclaimed. Azar’s last job was as Eli Lilly’s US chief. The sharp, Yale educated attorney did not have a rep for slashing drug prices at Lilly, which he left during a big executive reshuffle after Dave Ricks grabbed the CEO’s job.
He’ll be working with FDA commissioner Scott Gottlieb, another industry insider now in charge of regulating the business.
And he’ll be returning to HHS a second time. His earlier stint was general counsel and deputy secretary at the department in the George W Bush administration. Azar was on one of my panels about 16 months ago and ably provided the audience a sharp and concise representation of the kind of opportunities and pitfalls a Big Pharma like Lilly has to navigate every day.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 24,000+ biopharma pros who read Endpoints News by email every day.Free Subscription